The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides human antibodies that bind PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.

Claims

6 · 3 independent · depth 2

6 granted claims

›1.independentAn isolated monoclonal antibody or antigen binding portion thereof, having a heavy chain and a light chain, the heavy chain comprising a variable regi…+2

›2.independentAn isolated monoclonal antibody or antigen binding portion thereof, having a heavy chain and a light chain, wherein the light chain variable region ha…

›5.independentAn isolated antibody or antigen binding portion thereof selected from the group consisting ofna) An antibody or antigen binding portion thereof compri…+1

Classifications

6 codes

IPC · International Patent Classification

Section A — Human necessities

A61K39/395

Section C — Chemistry; metallurgy

C07K16/00

USPC · US Patent Classification

424/130.1530/387.1530/388.1424/141.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

4.1 y

1,503 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Examiner

Ruixiang Li

art unit 1646 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 27 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

2 Jun 2008

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 61058094	2 Jun 2008
related publication	US 20110059063 A1	10 Mar 2011

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.